RWE study highlights unmet needs in patients with NSCLC

  • The analysis included 855 patients with stage III NSCLC, including 475 who presented between 2015 and 2017 and 380 who presented between 2018 and 2019
  • Results showed that from 2015-2017 to 2018-2019, the proportion of patients undergoing CCRT increased from 34% to 42%
  • “In this real-world setting, only 52% of patients with stage III NSCLC were fit to undergo RITs consisting of approaches incorporating surgery or CCRT”

Merle I. Ronden, MD, Amsterdam University Medical Center

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: NOV2021BR002